Altimmune Inc (ALT)

May 02, 2025

What's Going On With Altimmune (ALT) Stock Today? - Benzinga

May 02, 2025

May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025

May 01, 2025

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 - The Manila Times

May 01, 2025

May 01, 2025

Altimmune, Inc. to Showcase Novel MASH Resolution Index Data for Pemvidutide at EASL International Liver Congress™ 2025 - Nasdaq

May 01, 2025

Apr 30, 2025

Altimmune to Participate in the Citizens Life Sciences Conferenc - GuruFocus

Apr 30, 2025

Apr 30, 2025

Altimmune to Participate in the Citizens Life Sciences Conference - Yahoo Finance

Apr 30, 2025

Apr 30, 2025

Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance

Apr 30, 2025

Apr 26, 2025

After losing 30% in the past year, Altimmune, Inc. (NASDAQ:ALT) institutional owners must be relieved by the recent gain - simplywall.st

Apr 26, 2025

Apr 20, 2025

Trading (ALT) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 20, 2025

Apr 11, 2025

Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com

Apr 11, 2025

Apr 10, 2025

Altimmune's US$42m Market Cap Fall Books Insider Losses - Yahoo

Apr 10, 2025

Apr 09, 2025

Coulter Partners places seasoned biopharmaceutical industry executives to Altimmune Board of Directors - Hunt Scanlon Media

Apr 09, 2025

Apr 08, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com Canada

Apr 08, 2025

Apr 08, 2025

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - Investing.com

Apr 08, 2025

Apr 04, 2025

H.C. Wainwright maintains Buy rating on Altimmune stock By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 04, 2025

H.C. Wainwright maintains Buy rating on Altimmune stock - Investing.com India

Apr 04, 2025

Apr 03, 2025

8 Analysts Assess Altimmune: What You Need To Know - Benzinga

Apr 03, 2025

Apr 03, 2025

Altimmune’s Pemvidutide: A Promising Catalyst with Blockbuster Potential and Strong Financial Backing - TipRanks

Apr 03, 2025

Apr 03, 2025

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN

Apr 03, 2025

Apr 02, 2025

JMP maintains Altimmune stock target at $25 on Phase 2b optimism - Investing.com

Apr 02, 2025

Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com

Mar 31, 2025

Mar 31, 2025

Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Mar 31, 2025

Mar 28, 2025

Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Mar 28, 2025

Mar 22, 2025

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo

Mar 22, 2025

Mar 19, 2025

Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN

Mar 19, 2025

Mar 19, 2025

10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey

Mar 19, 2025

Mar 17, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha

Mar 17, 2025

Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa

Mar 17, 2025